BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists

Cell Death and Differentiation

Volumn 17, Issue 5, 2010, Pages 872-882

  Goldsmith, K C ^a,b   Lestini, B J ^a   Gross, M ^a   Ip, L ^a   Bhumbla, A ^a   Zhang, X ^a   Zhao, H ^a   Liu, X ^a   Hogarty, M D ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bcl 2 homology proteins; BH3 mimetics; Chemoresistance; Experimental therapeutics; Neuroblastoma

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; CYTOCHROME C; ISOSORBIDE; PROTEIN BCL 2; PROTEIN BCL 2 ANTAGONIST; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MITOCHONDRION; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SOLID TUMOR;

APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE; CELL LINE, TUMOR; CYTOCHROMES C; GOSSYPOL; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MITOCHONDRIA; NEUROBLASTOMA; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 77950863805     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.171     Document Type: Article

References (40)

1. Walensky LD. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13: 1339-1350.
2. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121.
3. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008; 111: 2300-2309.
4. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171-185.
5. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388.
6. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3: 17-22.
7. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
8. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
9. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
10. Moreau C, Cartron PF, Hunt A, Meflah K, Green DR, Evan G et al. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J Biol Chem 2003; 278: 19426-19435.
11. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998; 58: 4453-4460. (Pubitemid 28450051)
12. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 2001; 61: 4864-4872.
13. Hogarty MD. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett 2003; 197: 173-179.
14. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
15. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293: 1829-1832.
16. Leung KT, Li KK, Sun SS, Chan PK, Ooi VE, Chiu LC. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL-a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 2008; 29: 544-551.
17. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
18. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
19. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-7129.
20. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
21. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121-132.
22. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG et al. BAX activation is initiated at a novel interaction site. Nature 2008; 455: 1076-1081.
23. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348-1358.
24. Uren RT, Dewson G, Chen L, Coyne SC, Huang DC, Adams JM et al. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol 2007; 177: 277-287.
25. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
26. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996; 10: 2859-2869.
27. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030-1039.
28. Hallaert DY, Spijker R, Jak M, Derks IA, Alves NL, Wensveen FM et al. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007; 14: 1958-1967.
29. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67: 782-791.
30. Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009; 8: 1587-1595.
31. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1181-1189. (Pubitemid 351555542)
32. Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970; 30: 2110-2118.
33. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP et al. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986; 76: 375-387.
34. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245-248.
35. Schlesinger HR, Gerson JM, Moorhead PS, Maguire H, Hummeler K. Establishment and characterization of human neuroblastoma cell lines. Cancer Res 1976; 36: 3094-3100.
36. Feder MK, Gilbert F. Clonal evolution in a human neuroblastoma. J Natl Cancer Inst 1983; 70: 1051-1056.
37. Schmechel D, Marangos PJ, Brightman M. Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 1978; 276: 834-836.
38. Goldsmith KC, Liu X, Dam V, Morgan BT, Shabbout M, Cnaan A et al. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene 2006; 25: 4525-4533.
39. Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004; 2: 363-372.
40. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.